Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelipepimut S - SELLAS Life Sciences Group

X
Drug Profile

Nelipepimut S - SELLAS Life Sciences Group

Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; NeuVax; NPS

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 16 Mar 2023 Discontinued - Phase-I for Gastric cancer in USA (Intradermal)
  • 16 Mar 2023 Discontinued - Phase-II for Breast cancer (Combination therapy, Neoadjuvant therapy) in USA (Intradermal)
  • 16 Mar 2023 Discontinued - Phase-III for Breast cancer (Early-stage disease, Prevention of relapse, Adjuvant therapy) in Bulgaria (Intradermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top